Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical diagnosis of idiopathic or genetic Cervical Dystonia~Exclusion Criteria:~* Current treatment with botulinum toxin of any type for any other indication (including aesthetic indications) and for any body region during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- Xeomin® Short Flex (Type: ACTIVE_COMPARATOR): short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
- Xeomin® Long Flex (Type: ACTIVE_COMPARATOR): long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.

Based on this trial design, predict the completion outcome and termination type (if applicable).